ADG-106
As of the edition of 20 October 2026, ADG-106 is a drug: stopped in 2023; acts on TNFRSF9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Unknown
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of ADG-106.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 | Q07011 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 1 | 2 | 1 |
| All trials | 8 |